
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics Inc. has completed a robust clinical program, specifically the CLARITY program, comprising three Phase 3 trials that demonstrated strong efficacy and a favorable safety profile, positioning the company for a potential market-leading role in the treatment of presbyopia. The company anticipates continued growth in annual spending levels, which could sustain momentum into fiscal year 2027 and beyond. Furthermore, LENZ is projected to achieve profitability by 2028, indicating a positive financial outlook and growth potential that could support an expansion of their sales force.
Bears say
LENZ Therapeutics faces significant commercial challenges in the presbyopia treatment sector, particularly related to altering established consumer behavior and the lack of a diversified product pipeline beyond its primary candidate, Vizz. The company must contend with competitive dynamics as well, as other presbyopia treatments are in development, which could affect Vizz’s market position even if those alternatives are currently at an earlier stage. Additionally, there are concerns regarding Vizz's intellectual property protection and the potential need for further funding or partnerships, which could impede the company's ability to maximize the value of its product offerings.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares